|
CASKIN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.95909963199392E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.27500010549397E-10 |
| Normal-vs-Stage2 |
3.13530001960771E-09 |
| Normal-vs-Stage3 |
2.642900E-04 |
| Normal-vs-Stage4 |
1.055060E-03 |
| Stage1-vs-Stage2 |
8.021800E-03 |
| Stage1-vs-Stage3 |
6.736500E-02 |
| Stage1-vs-Stage4 |
3.383200E-01 |
| Stage2-vs-Stage3 |
3.160000E-04 |
| Stage2-vs-Stage4 |
4.962700E-03 |
| Stage3-vs-Stage4 |
6.911000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.5269999688079E-09 |
| Normal-vs-AfricanAmerican |
3.646100E-04 |
| Normal-vs-Asian |
4.43319999998693E-06 |
| Caucasian-vs-AfricanAmerican |
1.271190E-01 |
| Caucasian-vs-Asian |
4.458000E-01 |
| AfricanAmerican-vs-Asian |
3.957600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.47650000009914E-07 |
| Normal-vs-Female |
3.25589555316697E-11 |
| Male-vs-Female |
4.681800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.22400003652746E-09 |
| Normal-vs-Age(41-60Yrs) |
3.27479998674107E-09 |
| Normal-vs-Age(61-80Yrs) |
3.38780000053163E-07 |
| Normal-vs-Age(81-100Yrs) |
2.517000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.798800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.833800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.861200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.656000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.876200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.745200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.97480000130312E-08 |
| Classical-VS-Follicular |
4.624000E-01 |
| Classical-VS-Other |
1.929350E-01 |
| Classical-VS-Normal |
8.60778115452376E-12 |
| Tall-VS-Follicular |
9.1534000046245E-08 |
| Tall-VS-Other |
3.872400E-01 |
| Tall-VS-Normal |
7.839600E-01 |
| Follicular-VS-Other |
1.111560E-01 |
| Follicular-VS-Normal |
1.86649995459476E-09 |
| Other-VS-Normal |
3.008000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.80030451552216E-11 |
| Normal-vs-N1 |
1.488170E-02 |
| N0-vs-N1 |
4.400300E-03 |
|
|
